The NO/sGC/cGMP pathway has been shown to be impaired in various cardiovascular diseases mainly by a reduced bioavailability of NO and, in parallel, by reducing the sensitivity of sGC towards its agonist NO [5], [7], [25], [26], [27]. This evidence concerns the gene SGCB and cardiovascular disorder.